Coping Strategies, Pain, and Quality of Life in Patients with Breast Cancer

Edyta Ośmialowska 1, Weronika Misiag 2, Mariusz Chabowski 3,4, * and Beata Jankowska-Polańska 1

1 Department of Clinical Nursing, Faculty of Health Science, Wroclaw Medical University, 51-618 Wroclaw, Poland; edziaosmial@wp.pl (E.O.); bianko@poczta.onet.pl (B.J.-P.)
2 Student Research Group No 180, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland; weronika.misiag@student.umed.wroc.pl
3 Department of Clinical Nursing, Division of Oncology and Palliative Care, Faculty of Health Science, Wroclaw Medical University, 51-618 Wroclaw, Poland
4 Department of Surgery, 4th Military Teaching Hospital, 50-981 Wroclaw, Poland
* Correspondence: mariusz.chabowski@gmail.com; Tel.: +48-261-660-247; Fax: +48-261-660-245

Abstract: Introduction: Each year, around 16,500 women in Poland are diagnosed with breast cancer, the second most common cause of death in women. In Poland, nearly 70,000 women live with breast cancer diagnosed within the last five years. Quality of life (QoL) research is particularly important in cancer patients, as it provides knowledge on their psychological and physical health, as well as the environment in which the patients function, all of which is essential to implementing multidisciplinary care involving the best use of the appropriate methods. Carrying the burden of cancer is a major challenge for patients. The strategy that patients use to cope with breast cancer significantly affects their quality of life. The purpose of the study is to assess the impact of coping strategies on the QoL in breast cancer patients. Material and Methods: The prospective study included a group of 202 women who had undergone surgical treatment for breast cancer at the Lower Silesian Cancer Center and who reported for follow-up appointments at the Oncology Clinic and the Surgical Oncology Clinic. For the study, we used the: EORTC QLQ-C30 cancer questionnaire, EORTC QLQ-BR23 module, Mental Adjustment to Cancer (Mini-MAC) scale, visual analog scale (VAS) for pain intensity, as well as the patients’ medical records, hospital records, and our own survey form. Results: The mean patient age was 53 years. Most patients had been diagnosed with cancer between one and two years before. In the women studied, there was a negative association between QoL and the choice of a destructive strategy for coping with cancer, and a positive one between QoL and a constructive coping strategy. Severe pain caused by the disease and its treatment significantly decreased the patients’ QoL in multiple domains. Conclusions: Patients choosing constructive strategies obtained higher QoL scores, while greater reliance on destructive coping strategies was associated with significantly worse QoL. In all functioning domains, higher levels of pain were associated with poorer QoL and more severe symptoms associated with the disease and its treatment.

Keywords: pain; quality of life; cancer coping strategy; Mini-MAC; EORTC QLQ–C30

1. Introduction

Each year, approximately 16,500 women in Poland [1] are diagnosed with breast cancer, the second most common cause of death in women [2]. In Poland, nearly 70,000 women live with breast cancer diagnosed within the last five years. The mean age at diagnosis is 61 years, but younger women are being increasingly often diagnosed with this type of cancer. Most deaths from breast cancer occur in women above 50 years of age (90%), and the risk of death increases with age [3]. The Polish National Cancer Registry reports that the incidence of breast cancer doubled in the last 30 years. In the year 2000, 11,853 patients were diagnosed with breast cancer, in 2010—more than 15,700, and in 2013—17,142.
The greatest increase in the risk of developing breast cancer has been noted in women aged 45–69 [4,5].

In cancer patients, quality of life (QoL) research is particularly important, as it enables a more comprehensive assessment and provides more insight into the patients’ psychological and physical health, as well as the environment in which they function. This additional information on patients’ QoL is essential to implementing multidisciplinary care involving the best use of the appropriate methods. QoL is shaped by socio-demographic factors, clinical factors including pain, and psycho-social factors such as acceptance of illness, strategies for coping with cancer, and strategies for coping with pain and stress. Determinants of QoL in women with breast cancer include pain, limitations in functioning, difficulties in daily activities, anxiety, and depression. Higher levels of anxiety are associated with greater feelings of hopelessness, more adverse effects of treatment after breast surgery, poorer body image, and poorer sexual functioning. An important aspect of QoL is the choice of the operating method. Breast reconstruction increases the esthetic satisfaction, which improves the patient well-being and QoL.

Pain caused by cancer can take two forms: physical and psychological. Pain severity is significantly correlated with physical, social, cognitive, emotional, and sexual functioning, body image, and future outlook.

Carrying the burden of cancer is a major challenge for patients. The strategy that patients use to cope with their breast cancer significantly affects their quality of life. A number of strategies for coping with cancer have been identified, including: fighting spirit, positive redefinition, helplessness/hopelessness, and anxious preoccupation.

The purpose of the study is to assess the impact of coping strategies on the QoL in breast cancer patients.

2. Materials and Methods

The prospective study included a group of 250 women who had undergone surgical treatment for breast cancer at the Lower Silesian Cancer Center and who reported for follow-up appointments at the Oncology Clinic and the Surgical Oncology Clinic. Forty-five patients dropped out during the study, either due to poor health or to a negative attitude toward the treatment. Moreover, three patients were excluded from the study due to the diagnosis of another cancer. There were no exclusions for severe depression or comorbidities. The following standardized instruments (validated in the Polish population) were used: The EORTC QLQ-C30 cancer questionnaire, the EORTC QLQ-BR23 breast-cancer-specific module, the Mental Adjustment to Cancer (Mini-MAC) scale, a visual analog scale (VAS) for pain intensity, as well as the patients’ medical records, hospital records, and the study’s own survey form assessing the patients’ clinical and socio-demographic situation.

The mean patient age was 53 (SD ± 10.3 years), the youngest patient was 26 years old, and the oldest was 75 years old. Most patients had been diagnosed with cancer between 1 and 2 years before the study (52.4%). The 22.8% of patients had been suffering from cancer for 2–5 years and 24.8% for over 5 years. Most patients had completed higher education (39.6%), were professionally active (63.9%), lived in urban areas (77.2%), and reported their financial standing and living conditions as good (63.4%). Single and childless women were a minority (24.3% and 14.9%, respectively).

In 53% of the surveyed patients, the disease was diagnosed during breast self-examination. As a result of screening mammography and during a visit to a doctor, respectively 25.7% and 21.3% of patients were diagnosed. In addition, 37.6% of the surveyed women underwent partial breast excision, 35.1% had a total amputation, and in 26.7% of the surveyed women breast amputation with simultaneous breast reconstruction were performed.

Inclusion criteria were: age between 18 and 75 years, diagnosis of early invasive breast cancer, primary surgical treatment with adjuvant chemotherapy or radiation therapy, and voluntary consent to participate. Exclusion criteria were: clinically advanced cancer (stage IV with metastasis), non-surgical treatment, another concurrent cancer or another
severe comorbidity (measured as the presence or absence), and severe depression requiring specialist treatment.

The study was approved on 24 April 2018 by the Medical University Bioethics Committee (approval no. KB–196/2018).

The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire on quality of life comprises 30 items for the assessment of the patient’s physical (5 items), role (2 items), emotional (4 items), cognitive (2 items), and social functioning (2 items). With 3 symptom scales and 6 individual items, the questionnaire also assesses fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties caused by the disease [6].

The EORTC QLQ-BR23 module provides a more accurate assessment of QoL in patients with breast cancer. It comprises 5 multi-item scales concerning body image, sexual functioning, treatment side effects, and breast- and arm-related symptoms. It also asks questions on the patient’s sexual enjoyment as well as their concerns about the prognosis and hair loss. The listed scales from both questionnaires represent a score range of 0–100 points. Greater intensity of a given characteristic corresponds to a higher score.

The Mental Adjustment to Cancer (Mini-MAC) scale evaluates the ways in which the patient copes with cancer. It identifies constructive and destructive strategies, including fighting spirit, positive redefinition, helplessness/hopelessness, and anxious preoccupation. Each strategy is rated using 7 statements. Scores in each category range between 7 and 28 points, and higher scores indicate a greater intensity of behaviors associated with a particular strategy [7].

A visual analogue scale (VAS) is an instrument comprising a numerical scale representing pain severity, with 0 standing for no pain at all, and 10 for unbearable pain. The self-designed questionnaire, the patients’ medical records, and hospital records allowed for assessing the age, education level, financial standing, professional activity, place of residence, stable relationship, and having children (Table 1) as well as the assessment of the clinical characteristics: the time of the diagnosis, the method of detection, and the type of surgery.

Table 1. General sociodemographic characteristics of the studied patients.

| Variable                  | n  (%)     |
|---------------------------|------------|
| 1. Number of respondents  | 202 (100%) |
| 2. Age (years)            |            |
| M ± SD                    | 53.0 ± 10.3|
| Me (Q1; Q3)               | 52 (45; 61)|
| Range                     | 26–75      |
| 3. Education              |            |
| Primary                   | 9 (4.5%)   |
| Vocational                | 35 (17.3%) |
| High school               | 78 (38.6%) |
| College/university        | 80 (39.6%) |
| 4. Financial standing     |            |
| Very good                 | 36 (17.8%) |
| Good                      | 128 (63.4%)|
| Unsatisfactory            | 35 (17.3%) |
| Poor                      | 3 (1.5%)   |
| 5. Professional activity  |            |
| Yes                       | 129 (63.9%)|
| No                        | 73 (36.1%) |
| 6. Residence              |            |
| Urban                     | 156 (77.2%)|
| Rural                     | 46 (22.8%) |
3. Results

Comparative analysis of QoL in the sexual functioning (BRSEF) and sexual enjoyment (BRSEE) domains demonstrated associations with some socio-demographic variables ($p < 0.05$), listed in Tables 2 and 3.

Table 1. Cont.

| Variable                               | n (%)   |
|----------------------------------------|---------|
| 7. In a stable relationship            |         |
| Yes                                    | 153 (75.7%) |
| No                                     | 49 (24.3%)  |
| 8. Children                            |         |
| Yes                                    | 172 (85.1%) |
| No                                     | 30 (14.9%)  |
| 9. Number of children                  |         |
| 0                                       | 39 (19.3%) |
| 1                                       | 72 (35.6%) |
| 2                                       | 76 (37.6%) |
| 3 and more                             | 15 (7.4%)  |

M—mean; SD—standard deviation; Me—median; Q₁—lower quartile; Q₃—upper quartile; n—number; %—percentage.

Statistical analysis results for qualitative variables are shown in contingency tables as numbers (n) and percentages (%), with the chi-squared test used to assess the strength of association between two variables. For quantitative variables, distribution normality was verified using the Kolmogorov–Smirnov or Shapiro–Wilk test. Means for quantitative variables in multiple groups were compared using a single-factor analysis of variance (ANOVA). All analyses used a significance threshold of $p < 0.05$, and Tukey’s LSD test was used to perform the analyses.

Table 2. Sexual functioning (EORTC QLQ-BR23 BRSEF domain) in patients differing in terms of selected socio-demographic and clinical characteristics, with test results.

| Characteristic (Variable)                              | BRSEF M ± SD | Test Result |
|-------------------------------------------------------|--------------|-------------|
| 1. Age (years)                                        | 0.179        |
| 2. Education                                          | 0.980        |
| 3. Financial standing                                 | 0.054        |
| 4. Professional activity                              | 0.628        |
| 5. Residence                                          |              |
| Urban                                                 | 47.8 ± 32.7  |
| Rural                                                 | 33.8 ± 29.2  |
| 6. In a stable relationship                           | 0.312        |
| 7. Has children                                       | 0.179        |
| 8. Duration of illness (years)                        | 0.084        |
| 9. Disease diagnosed during a doctor’s visit:         |              |
| No                                                    | 45.3 ± 34.4  |
| Yes                                                   | 34.7 ± 29.1  |
| 10. Chronic illness                                   | 0.064        |
Table 2. Cont.

| Characteristic (Variable) | BRSEF Test Result |
|---------------------------|--------------------|
| M ± SD                    | p                  |
| 11. Satisfied with treatment: |                     |
| Yes                       | 61.7 ± 23.6        | 0.001 |
| Yes, moderately           | 38.9 ± 25.7        |      |
| Rather not                | 37.9 ± 29.0        |      |
| No                        | 32.5 ± 30.9        |      |
| 12. Time from the procedure |                     | 0.464 |
| 13. Cosmetic result:      |                     |
| Very good                 | 55.0 ± 26.1        | <0.001|
| Good                      | 53.4 ± 25.7        |      |
| Poor                      | 37.0 ± 30.0        |      |
| Very poor                 | 26.3 ± 30.0        |      |
| 14. Negative impact of the surgery on personal life: |                     |
| Yes, major impact         | 18.9 ± 20.4        | <0.001|
| Yes, minor impact         | 31.2 ± 30.7        |      |
| No impact                 | 50.3 ± 29.1        |      |

Table 3. Sexual enjoyment (EORTC QLQ-BR23 BRSEE domain) in patients differing in terms of selected socio-demographic and clinical characteristics, with test results.

| Characteristic (Variable) | BRSEF Test Result |
|---------------------------|--------------------|
| M ± SD                    | p                  |
| 1. Age (years)            |                     |
| 46 or earlier             | 49.6 ± 37.4        | 0.022 |
| 47–59                     | 39.8 ± 33.9        |      |
| 60 or more                | 29.2 ± 34.5        |      |
| 2. Education              |                     |
| Primary or vocational     | 27.4 ± 32.3        | 0.025 |
| High school               | 38.8 ± 34.0        |      |
| College/university        | 46.9 ± 37.4        |      |
| 3. Financial standing     |                     |
| Very good                 | 52.9 ± 34.0        | <0.001|
| Good                      | 42.9 ± 35.6        |      |
| Unsatisfactory or poor    | 14.0 ± 24.0        |      |
| 4. Professional activity  |                     |
| No                        | 28.6 ± 34.5        | 0.005 |
| Yes                       | 44.8 ± 35.1        |      |
| 5. Residence              |                     |
| Urban                     | 42.5 ± 36.8        | 0.038 |
| Rural                     | 29.3 ± 30.0        |      |
| 6. In a stable relationship|                     |
| No                        | 21.9 ± 35.2        | 0.001 |
| Yes                       | 43.9 ± 34.4        |      |
| 7. Has children           | 0.137              |      |
| 8. Duration of illness (years) |                     | 0.995 |
| 9. Disease diagnosed during a doctor’s visit |                     | 0.176 |
| 10. Comorbidities         |                     |
| No                        | 41.2 ± 35.6        | 0.009 |
| Yes                       | 12.1 ± 22.5        |      |
Table 3. Cont.

| Characteristic (Variable) | BRSEE Test Result |
|---------------------------|-------------------|
|                           | M ± SD             |
| 11. Satisfaction with treatment | 0.099             |
| 12. Time from the procedure | 0.358             |
| 13. Cosmetic result        | 0.077             |

14. Negative impact of the surgery on personal life
   - Yes, major impact: 33.3 ± 34.0
   - Yes, minor impact: 39.0 ± 34.9
   - No impact: 49.6 ± 37.4

Analysis of mental adaptation to cancer based on Mini-MAC scores showed that the most common coping strategies in the cancer patients studied were fighting spirit and positive redefinition (Table 4). Anxious preoccupation and helplessness/hopelessness were the least common. The vast majority preferred the constructive coping style (22.8 ± 2.7, or standard ten (sten) 7.0 ± 1.4) to the destructive coping style (14.3 ± 4.1, or sten score 3.6 ± 2.0).

Table 4. Mini-MAC questionnaire scores.

| Cancer Coping Strategy                  | Results (n) |
|-----------------------------------------|-------------|
| Anxious preoccupation (points)          |             |
| M ± SD                                  | 16.6 ± 4.5  |
| Me (Q1; Q3)                             | 17 (13; 20) |
| Min–Max                                 | 7–28        |
| Fighting spirit (points)                |             |
| M ± SD                                  | 23.3 ± 3.4  |
| Me (Q1; Q3)                             | 24 (21; 26) |
| Min–Max                                 | 4–28        |
| Helplessness/hopelessness (points)      |             |
| M ± SD                                  | 11.9 ± 4.4  |
| Me (Q1; Q3)                             | 11 (9; 14)  |
| Min–Max                                 | 6–25        |
| Positive redefinition (points)          |             |
| M ± SD                                  | 22.3 ± 3.1  |
| Me (Q1; Q3)                             | 23 (21; 25) |
| Min–Max                                 | 7–28        |
| Constructive style (points)             |             |
| M ± SD                                  | 22.8 ± 2.7  |
| Me (Q1; Q3)                             | 24 (22; 25) |
| Min–Max                                 | 16–28       |
| Destructive style (points)              |             |
| M ± SD                                  | 14.3 ± 4.1  |
| Me (Q1; Q3)                             | 14 (11; 17) |
| Min–Max                                 | 7–25        |
| Constructive style (sten)               |             |
| M ± SD                                  | 7.0 ± 1.4   |
| Me (Q1; Q3)                             | 7 (6; 8)    |
| Min–Max                                 | 4–10        |
Table 4. Cont.

| Cancer Coping Strategy         | Results (n) |
|-------------------------------|-------------|
| Destructive style (sten)      |             |
| \(M \pm SD\)                 | 3.6 ± 2.0   |
| \(Me (Q_1; Q_3)\)            | 4 (2; 9)    |
| \(Min–Max\)                  | 1–8         |
| Constructive style            |             |
| Low score                     | n           |
|                              | 5           |
| Moderate score                | 69          |
| High score                    | 128         |
|                              | %           |
| Low score                     | 2.5         |
| Moderate score                | 34.2        |
| High score                    | 63.4        |

\(M\)—mean; \(SD\)—standard deviation; \(Me\)—median; \(Q_1\)—lower quartile; \(Q_3\)—upper quartile; \(Min\)—lowest value; \(Max\)—highest value; \(n\)—number; \(\%\)—percentage.

Our analysis of general QoL based on the EORTC QLQ-C30 questionnaire in the group with a constructive coping strategy (identified by the Mini-MAC) only demonstrated a statistically significant relationship in terms of role functioning (Table 5). High scores for constructive coping were associated with an RF score of 23.3 ± 19.0, compared to 17.1 ± 22.0 for low ones (\(p = 0.047\)). In turn, in the analysis of relationships between QoL measured by the EORTC QLQ-BR23 questionnaire and the constructive coping strategy identified by the Mini-MAC, a significant relationship was only found with the “arm-related symptoms” domain (Table 6).

Table 5. Quality of life (EORTC QLQ-30C scores) in patients differing in terms of scores for the constructive coping strategy (Mini-MAC), with analysis of variance results.

| QoL Evaluation—EORTC QLQ-30C | Constructive Coping Strategy (Mini-MAC) | ANOVA \(p\) |
|------------------------------|------------------------------------------|-------------|
|                              | Low Score Sten 0–4 \(n = 5\)               | Moderate Score Sten 5–6 \(n = 69\) | High Score Sten 7–10 \(n = 128\) |
| General health (QL)          | \(M \pm SD\)                              | 45.0 ± 23.3 | 55.2 ± 18.9 | 60.1 ± 21.3 |
|                              | \(Me (Q_1; Q_3)\)                         | 33 (33; 50) | 58 (42; 67) | 67 (50; 75) |
|                              | \(Min–Max\)                              | 25–83       | 0–100       | 0–100       |
| Physical functioning (PF)    | \(M \pm SD\)                              | 23.8 ± 17.2 | 23.5 ± 17.2 | 38.7 ± 20.8 |
|                              | \(Me (Q_1; Q_3)\)                         | 20 (13; 27) | 20 (13; 33) | 40 (33; 53) |
|                              | \(Min–Max\)                              | 0–87        | 0–73        | 7–60        |
| Role functioning (RF)        | \(M \pm SD\)                              | 17.1 ± 22.0 | 24.9 ± 19.9 | 23.3 ± 19.0 |
|                              | \(Me (Q_1; Q_3)\)                         | 17 (0; 17)  | 17 (17; 33) | 17 (17; 33) |
|                              | \(Min–Max\)                              | 0–100       | 0–67        | 0–50        |
| Emotional functioning (EF)   | \(M \pm SD\)                              | 35.9 ± 23.5 | 39.5 ± 24.8 | 58.3 ± 36.3 |
|                              | \(Me (Q_1; Q_3)\)                         | 33 (17; 50) | 33 (25; 58) | 67 (50; 83) |
|                              | \(Min–Max\)                              | 0–100       | 0–92        | 0–92        |
| Cognitive functioning (CF)   | \(M \pm SD\)                              | 23.3 ± 22.4 | 25.6 ± 23.8 | 24.3 ± 25.9 |
|                              | \(Me (Q_1; Q_3)\)                         | 33 (0; 33)  | 17 (0; 33)  | 17 (0; 33)  |
|                              | \(Min–Max\)                              | 0–50        | 0–83        | 0–100       |
Table 5. Cont.

| QoL Evaluation—EORTC QLQ-30C | Constructive Coping Strategy (Mini-MAC) | ANOVA p |
|-----------------------------|-----------------------------------------|--------|
|                             | Low Score Sten 0–4 n = 5 | Moderate Score Sten 5–6 n = 69 | High Score Sten 7–10 n = 128 |

Social functioning (SF)

- **M ± SD**
  - 27.6 ± 22.1
  - 31.4 ± 27.3
  - 43.3 ± 27.9

- **M** (Q1; Q3)
  - 33 (17; 33)
  - 33 (17; 50)
  - 50 (33; 67)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–67

Fatigue (FA)

- **M ± SD**
  - 57.8 ± 28.8
  - 42.7 ± 21.8
  - 37.6 ± 21.5

- **M** (Q1; Q3)
  - 67 (56; 67)
  - 33 (33; 56)
  - 33 (22; 56)

- **Min–Max**
  - 11–89
  - 0–100
  - 0–100

Nausea and vomiting (NV)

- **M ± SD**
  - 36.7 ± 27.4
  - 16.4 ± 25.6
  - 13.0 ± 25.9

- **M** (Q1; Q3)
  - 50 (17; 50)
  - 0 (0; 33)
  - 0 (0; 17)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–100

Pain (PA)

- **M ± SD**
  - 46.7 ± 27.4
  - 31.2 ± 25.6
  - 26.0 ± 24.7

- **M** (Q1; Q3)
  - 50 (50; 67)
  - 33 (33; 50)
  - 33 (22; 56)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–100

Dyspnea (DY)

- **M ± SD**
  - 13.3 ± 18.3
  - 16.2 ± 24.8
  - 13.5 ± 26.3

- **M** (Q1; Q3)
  - 0 (0; 33)
  - 0 (0; 33)
  - 0 (0; 17)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–100

Insomnia (SL)

- **M ± SD**
  - 53.3 ± 38.0
  - 37.3 ± 33.8
  - 41.7 ± 33.2

- **M** (Q1; Q3)
  - 67 (33; 67)
  - 33 (0; 67)
  - 33 (0; 67)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–100

Appetite loss (AP)

- **M ± SD**
  - 46.7 ± 38.0
  - 21.3 ± 25.5
  - 19.5 ± 28.5

- **M** (Q1; Q3)
  - 33 (33; 67)
  - 0 (0; 33)
  - 0 (0; 33)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–100

Constipation (CO)

- **M ± SD**
  - 26.7 ± 27.9
  - 20.8 ± 25.6
  - 20.6 ± 24.4

- **M** (Q1; Q3)
  - 33 (0; 33)
  - 0 (0; 33)
  - 0 (0; 33)

- **Min–Max**
  - 0–67
  - 0–100
  - 0–100

Diarrhea (DI)

- **M ± SD**
  - 26.7 ± 43.5
  - 9.2 ± 24.2
  - 11.2 ± 21.0

- **M** (Q1; Q3)
  - 0 (0; 33)
  - 0 (0; 0)
  - 0 (0; 33)

- **Min–Max**
  - 0–100
  - 0–100
  - 0–100

Financial difficulties (FI)

- **M ± SD**
  - 20.0 ± 18.3
  - 29.4 ± 31.3
  - 30.7 ± 29.8

- **M** (Q1; Q3)
  - 33 (0; 33)
  - 33 (0; 33)
  - 33 (0; 33)

- **Min–Max**
  - 0–33
  - 0–100
  - 0–100

M—mean; SD—standard deviation; M—median; Q1—lower quartile; Q3—upper quartile; Min—lowest value; Max—highest value.

When associations between QoL (EORTC QLQ-C30) and the destructive coping strategy (Mini-MAC) were analyzed, significant correlations were found in all functioning domains. Higher scores for the destructive strategy were associated with poorer QoL. Analysis results are shown in Table 7, with significant associations identified at p < 0.001. Similarly to EORTC QLQ-C30, EORTC QLQ-BR23 scores were also correlated with scores for the destructive coping strategy (Table 8). The most significant changes in QoL were found in the body image, sexual functioning, and future outlook domains (p < 0.001).
The choice of this strategy was also associated with more severe disease symptoms and treatment adverse effects, as shown in Table 8.

To analyze the relationship between QoL and pain levels, comparative analysis of EORTC QLQ-C30 and VAS scores was performed. Higher pain levels were associated with poorer perceived QoL in the following domains: general health, physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning ($p < 0.001$) (Table 9).

### Table 6. Quality of life (EORTC QLQ-BR23 scores) in patients differing in terms of scores for the constructive coping strategy, with analysis of variance results.

| Functioning Scales (QLQ-BR23) | Low Score (Sten 0–4) | Moderate Score (Sten 5–6) | High Score (Sten 7–10) | ANOVA $p$ |
|--------------------------------|----------------------|---------------------------|------------------------|----------|
| **Body image (BRBI)** | | | | |
| $M \pm SD$ | 36.7 ± 24.7 | 37.1 ± 26.3 | 40.2 ± 29.1 | 0.743 |
| $Me$ ($Q_1$; $Q_3$) | 33 (33; 50) | 33 (17; 58) | 33 (17; 58) | |
| $Min$–$Max$ | 0–67 | 0–100 | 0–100 | |
| **Sexual functioning (BRSEF)** | | | | |
| $M \pm SD$ | 33.3 ± 23.6 | 35.5 ± 28.7 | 37.9 ± 31.8 | 0.842 |
| $Me$ ($Q_1$; $Q_3$) | 33 (33; 33) | 33 (17; 50) | 33 (0; 67) | |
| $Min$–$Max$ | 0–67 | 0–100 | 0–100 | |
| **Sexual enjoyment (BRSEE)** | | | | |
| $M \pm SD$ | 16.7 ± 23.5 | 38.4 ± 37.6 | 40.1 ± 34.7 | 0.640 |
| $Me$ ($Q_1$; $Q_3$) | 17 (8; 25) | 33 (0; 67) | 33 (0; 67) | |
| $Min$–$Max$ | 0–33 | 0–100 | 0–100 | |
| **Future outlook (BRFU)** | | | | |
| $M \pm SD$ | 73.3 ± 36.5 | 68.1 ± 31.5 | 74.3 ± 29.5 | 0.398 |
| $Me$ ($Q_1$; $Q_3$) | 100 (33; 100) | 67 (33; 100) | 100(33;100) | |
| $Min$–$Max$ | 33–100 | 0–100 | 0–100 | |
| **Systemic treatment adverse effects (BRST)** | | | | |
| $M \pm SD$ | 45.3 ± 14.7 | 26.0 ± 17.6 | 30.4 ± 20.8 | 0.061 |
| $Me$ ($Q_1$; $Q_3$) | 52 (33; 52) | 24 (14; 38) | 29 (14; 43) | |
| $Min$–$Max$ | 27–62 | 0–62 | 0–100 | |
| **Breast-related symptoms (BRBS)** | | | | |
| $M \pm SD$ | 46.7 ± 33.6 | 25.6 ± 21.7 | 28.3 ± 26.6 | 0.190 |
| $Me$ ($Q_1$; $Q_3$) | 58 (25; 67) | 25 (8; 42) | 25 (8; 50) | |
| $Min$–$Max$ | 0–83 | 0–75 | 0–92 | |
| **Arm-related symptoms (BRAS)** | | | | |
| $M \pm SD$ | 38.7 ± 25.3 | 29.5 ± 21.5 | 33.3 ± 24.9 | 0.038 |
| $Me$ ($Q_1$; $Q_3$) | 33 (19; 56) | 22 (11; 44) | 33 (22; 44) | |
| $Min$–$Max$ | 0–100 | 0–89 | 0–67 | |
| **Concern about hair loss (BRHL)** | | | | |
| $M \pm SD$ | 41.7 ± 50.0 | 45.2 ± 31.1 | 60.1 ± 35.7 | 0.076 |
| $Me$ ($Q_1$; $Q_3$) | 33 (0; 75) | 33 (33; 67) | 67 (33; 100) | |
| $Min$–$Max$ | 0–100 | 0–100 | 0–100 | |

$M$—mean; $SD$—standard deviation; $Me$—median; $Q_1$—lower quartile; $Q_3$—upper quartile; $Min$—lowest value; $Max$—highest value.
Table 7. Quality of life (EORTC QLQ-30C scores) in patients differing in terms of scores for the destructive coping strategy (Mini-MAC), with analysis of variance results.

| QoL Evaluation—EORTC QLQ-30C | Destructive Coping Strategy (Mini-MAC) | ANOVA | p |
|------------------------------|----------------------------------------|-------|---|
|                             | Low Score Sten 0–4 n = 126 | Moderate Score Sten 5–6 n = 59 | High Score Sten 7–10 n = 17 |
| General health (QL) | | | |
| M ± SD | 64.0 ± 17.5 | 55.7 ± 16.6 | 22.5 ± 18.8 | <0.001 |
| Me (Q1; Q3) | 67 (50; 81) | 58 (50; 67) | 17 (8; 33) |
| Min–Max | 17–100 | 8–83 | 0–58 |
| Physical functioning (PF) | | | |
| M ± SD | 60.6 ± 16.3 | 20.5 ± 12.3 | 20.8 ± 13.5 | <0.001 |
| Me (Q1; Q3) | 60 (53; 73) | 20 (13; 27) | 20 (13; 27) |
| Min–Max | 20–87 | 0–60 | 0–60 |
| Role functioning (RF) | | | |
| M ± SD | 60.8 ± 22.0 | 15.3 ± 15.3 | 16.5 ± 17.9 | <0.001 |
| Me (Q1; Q3) | 67 (50; 67) | 17 (0; 17) | 17 (0; 33) |
| Min–Max | 17–100 | 0–67 | 0–67 |
| Emotional functioning (EF) | | | |
| M ± SD | 71.6 ± 14.5 | 44.8 ± 24.2 | 29.7 ± 20.5 | <0.001 |
| Me (Q1; Q3) | 75 (67; 83) | 42 (25; 67) | 25 (17; 33) |
| Min–Max | 42–92 | 0–100 | 0–92 |
| Cognitive functioning (CF) | | | |
| M ± SD | 63.7 ± 23.7 | 25.1 ± 22.8 | 19.3 ± 21.4 | <0.001 |
| Me (Q1; Q3) | 67 (50; 83) | 17 (0; 33) | 17 (0; 33) |
| Min–Max | 33–100 | 0–100 | 0–83 |
| Social functioning (SF) | | | |
| M ± SD | 63.7 ± 18.9 | 37.9 ± 24.7 | 20.6 ± 18.4 | <0.001 |
| Me (Q1; Q3) | 67 (50; 83) | 33 (25; 50) | 17 (0; 33) |
| Min–Max | 33–100 | 0–100 | 0–83 |
| Fatigue (FA) | | | |
| M ± SD | 37.5 ± 21.8 | 38.4 ± 20.5 | 62.1 ± 16.7 | <0.001 |
| Me (Q1; Q3) | 33 (22; 53) | 33 (22; 56) | 67 (44; 78) |
| Min–Max | 0–100 | 0–100 | 33–89 |
| Nausea and vomiting (NV) | | | |
| M ± SD | 8.1 ± 19.4 | 14.7 ± 22.5 | 64.7 ± 26.3 | <0.001 |
| Me (Q1; Q3) | 0 (0; 0) | 0 (0; 33) | 67 (50; 83) |
| Min–Max | 0–100 | 0–100 | 17–100 |
| Pain (PA) | | | |
| M ± SD | 23.8 ± 23.0 | 28.2 ± 24.0 | 61.8 ± 20.2 | <0.001 |
| Me (Q1; Q3) | 17 (0; 33) | 33 (17; 33) | 67 (50; 67) |
| Min–Max | 0–100 | 0–100 | 17–100 |
| Dyspnea (DY) | | | |
| M ± SD | 11.6 ± 21.6 | 7.9 ± 18.9 | 60.4 ± 30.4 | <0.001 |
| Me (Q1; Q3) | 0 (0; 33) | 0 (0; 0) | 67 (58; 67) |
| Min–Max | 0–100 | 0–67 | 0–100 |
| Insomnia (SL) | | | |
| M ± SD | 35.7 ± 34.0 | 42.0 ± 30.9 | 70.6 ± 20.0 | <0.001 |
| Me (Q1; Q3) | 33 (0; 67) | 33 (33; 67) | 67 (67; 67) |
| Min–Max | 0–100 | 0–100 | 33–100 |
| Appetite loss (AP) | | | |
| M ± SD | 13.2 ± 21.1 | 23.7 ± 30.4 | 66.7 ± 16.7 | <0.001 |
| Me (Q1; Q3) | 0 (0; 33) | 0 (0; 33) | 67 (67; 67) |
| Min–Max | 0–100 | 0–100 | 33–100 |
Table 7. Cont.

| QoL Evaluation—EORTC QLQ-30C | Destructive Coping Strategy (Mini-MAC) | ANOVA |
|-----------------------------|----------------------------------------|-------|
|                             | Low Score Sten 0–4 n = 126             |       |
|                             | Moderate Score Sten 5–6 n = 59         |       |
|                             | High Score Sten 7–10 n = 17            |       |
| Constipation (CO)           |                                       |       |
| M ± SD                      | 17.2 ± 24.1                           |       |
| Me (Q1; Q3)                 | 0 (0; 33)                              |       |
| Min–Max                     | 0–100                                  |       |
| Moderate Score               | 19.8 ± 21.5                           |       |
| Sten 5–6 n = 59             | 33 (0; 33)                             |       |
| High Score                  | 51.0 ± 20.8                            |       |
| Sten 7–10 n = 17            | 67 (33; 67)                            | <0.001|
| Constipation (CO)           |                                       |       |
| M ± SD                      | 22.8 ± 24.8                           |       |
| Me (Q1; Q3)                 | 33 (0; 33)                             |       |
| Min–Max                     | 0–100                                  |       |
| Financial difficulties (FI) |                                       |       |
| M ± SD                      | 22.8 ± 24.8                           |       |
| Me (Q1; Q3)                 | 33 (0; 33)                             |       |
| Min–Max                     | 0–100                                  |       |

$M$—mean; $SD$—standard deviation; $Me$—median; $Q_1$—lower quartile; $Q_3$—upper quartile; $Min$—lowest value; $Max$—highest value.

Table 8. Quality of life (EORTC QLQ-BR23 scores) in patients differing in terms of scores for the destructive coping strategy, with analysis of variance results.

| Functioning Scales QLQ-BR23 | Destructive Coping Strategy (Mini-MAC) | ANOVA |
|------------------------------|----------------------------------------|-------|
|                             | Low Score Sten 0–4 n = 126             |       |
|                             | Moderate Score Sten 5–6 n = 59         |       |
|                             | High Score Sten 7–10 n = 17            |       |
| Body image (BRBI)           |                                       |       |
| M ± SD                      | 64.2 ± 13.4                           |       |
| Me (Q1; Q3)                 | 67 (58; 75)                            |       |
| Min–Max                     | 33–83                                  |       |
| Sexual functioning (BRSEF)  |                                       |       |
| M ± SD                      | 64.7 ± 16.5                           |       |
| Me (Q1; Q3)                 | 67 (50; 83)                            |       |
| Min–Max                     | 33–83                                  |       |
| Sexual enjoyment (BRSEE)     |                                       |       |
| M ± SD                      | 44.0 ± 37.1                           |       |
| Me (Q1; Q3)                 | 33 (0; 67)                             |       |
| Min–Max                     | 0–100                                  |       |
| Future outlook (BRFU)        |                                       |       |
| M ± SD                      | 72.6 ± 27.0                           |       |
| Me (Q1; Q3)                 | 67 (67; 100)                           |       |
| Min–Max                     | 33–100                                 |       |
| Systemic treatment adverse  |                                       |       |
| effects (BRST)              |                                       |       |
| M ± SD                      | 23.3 ± 16.4                           |       |
| Me (Q1; Q3)                 | 19 (10; 33)                            |       |
| Min–Max                     | 0–71                                   |       |
| Breast-related symptoms     |                                       |       |
| (BRBS)                      |                                       |       |
| M ± SD                      | 20.0 ± 22.7                           |       |
| Me (Q1; Q3)                 | 8 (0; 33)                              |       |
| Min–Max                     | 0–92                                   |       |
Table 8. Cont.

| Functioning Scales | Destructive Coping Strategy (Mini-MAC) | ANOVA p |
|---------------------|----------------------------------------|---------|
|                     | Low Score Sten 0–4 n = 126             | Moderate Score Sten 5–6 n = 59 | High Score Sten 7–10 n = 17 |
|                     | M ± SD                                  | M ± SD                          | M ± SD                          |
|                     | Me (Q1; Q3)                             | Me (Q1; Q3)                     | Me (Q1; Q3)                     |
|                     | Min–Max                                | 0–100                           | 0–100                           |
| Arm-related symptoms (BRAS) | 28.2 ± 21.4                           | 43.1 ± 24.7                     | 62.1 ± 16.2                     | <0.001 |
|                     | 22 (11; 44)                             | 44 (22; 67)                     | 56 (56; 78)                     |
| Concern about hair loss (BRHL) | 40.9 ± 35.7                           | 70.2 ± 30.8                     | 60.8 ± 24.3                     | <0.001 |
|                     | 33 (0; 67)                             | 67 (67; 100)                    | 67 (67; 67)                     |

M—mean; SD—standard deviation; Me—median; Q1—lower quartile; Q3—upper quartile; Min—lowest value; Max—highest value.

Table 9. Quality of life (EORTC QLQ-BR23 scores) in patients differing in terms of pain severity scores, with analysis of variance results.

| QoL Evaluation—EORTC QLQ-30C | Pain Severity (VAS) | ANOVA p |
|-------------------------------|---------------------|---------|
|                               | Mild 0–2 Points n = 100 | Moderate 2–4 Points n = 52 | Severe 4–10 Points n = 50 |
| General health (QL)           | 68.3 ± 13.5         | 58.3 ± 16.3               | 37.2 ± 21.3                  | <0.001 |
|                               | 67 (58; 83)         | 58 (50; 67)               | 33 (25; 50)                 |
| Physical functioning (PF)     | 41.7 ± 20.3         | 22.5 ± 11.2               | 16.0 ± 11.0                 | <0.001 |
|                               | 40 (27; 58)         | 20 (13; 27)               | 13 (7; 20)                  |
| Role functioning (RF)         | 43.0 ± 23.4         | 19.9 ± 14.8               | 8.3 ± 12.2                  | <0.001 |
|                               | 50 (17; 62)         | 17 (17; 33)               | 0 (0; 17)                   |
| Emotional functioning (EF)    | 60.0 ± 20.9         | 42.6 ± 21.1               | 23.9 ± 17.6                 | <0.001 |
|                               | 67 (42; 75)         | 33 (31; 58)               | 25 (17; 33)                |
| Cognitive functioning (CF)    | 46.0 ± 29.1         | 25.6 ± 20.5               | 13.7 ± 17.0                 | <0.001 |
|                               | 33 (33; 67)         | 33 (0; 33)                | 17 (6; 17)                  |
| Social functioning (SF)       | 49.0 ± 24.8         | 30.4 ± 21.8               | 18.8 ± 18.1                 | <0.001 |
|                               | 50 (33; 67)         | 33 (17; 37)               | 17 (0; 33)                  |

M—mean; SD—standard deviation; Me—median; Q1—lower quartile; Q3—upper quartile; Min—lowest value; Max—highest value.

Comparative analysis of EORTC QLQ-BR23 and VAS scores demonstrated better functioning in patients with mild or moderate pain, compared to those experiencing severe pain, in terms of: body image (p < 0.001), sexual functioning (p < 0.001); no statistically
significant association was found in terms of sexual enjoyment (p = 0.021) or future outlook (p = 0.023) (Table 10). More severe symptoms in most EORTC QLQ-BR23 domains were also observed in patients with high VAS pain scores (Table 10).

### Table 10. Quality of life (EORTC QLQ-BR23 scores) in patients differing in terms of pain severity scores, with analysis of variance results.

| Functioning Scales           | Pain Severity (VAS) | ANOVA | P  |
|------------------------------|---------------------|-------|----|
|                              | Mild 0–2 Points  | Moderate 2–4 Points | Severe 4–10 Points | |
|                              | n = 100             | n = 52 | n = 50 | |
| Body image (BRBI)            |                     |       |       | |
| M ± SD                       | 46.2 ± 28.3         | 47.1 ± 30.1 | 31.3 ± 24.7 | <0.001 |
| Me (Q1; Q3)                  | 46 (25; 67)         | 33 (33; 75) | 33 (8; 50) | |
| Min–Max                      | 0–100               | 0–100 | 0–100 | |
| Sexual functioning (BRSEF)   |                     |       |       | |
| M ± SD                       | 46.3 ± 28.2         | 45.2 ± 33.4 | 28.0 ± 27.6 | <0.001 |
| Me (Q1; Q3)                  | 50 (21; 67)         | 33 (33; 67) | 33 (0; 33) | |
| Min–Max                      | 0–100               | 0–100 | 0–100 | |
| Sexual enjoyment (BRSEE)     |                     |       |       | |
| M ± SD                       | 41.0 ± 33.5         | 47.7 ± 35.5 | 27.0 ± 37.0 | 0.021 |
| Me (Q1; Q3)                  | 33 (0; 67)          | 33 (33; 67) | 0 (0; 67) | |
| Min–Max                      | 0–100               | 0–100 | 0–100 | |
| Future outlook (BRFU)        |                     |       |       | |
| M ± SD                       | 80.7 ± 27.0         | 74.4 ± 30.0 | 66.7 ± 31.2 | 0.023 |
| Me (Q1; Q3)                  | 100(67;100)         | 100(33;100) | 67 (33; 100) | |
| Min–Max                      | 0–100               | 0–100 | 0–100 | |
| Systemic treatment adverse  |                     |       |       | |
| effects (BRST)               |                     |       |       | |
| M ± SD                       | 21.0 ± 17.5         | 30.8 ± 17.7 | 44.3 ± 17.4 | <0.001 |
| Me (Q1; Q3)                  | 14 (10; 29)         | 29 (14; 43) | 43 (33; 37) | |
| Min–Max                      | 0–100               | 0–67 | 5–76 | |
| Breast-related symptoms (BRBS) |                     |       |       | |
| M ± SD                       | 16.7 ± 19.4         | 28.9 ± 20.9 | 48.7 ± 26.5 | <0.001 |
| Me (Q1; Q3)                  | 8 (0; 25)           | 33 (8; 42) | 50 (33; 73) | |
| Min–Max                      | 0–92                | 0–67 | 0–92 | |
| Arm-related symptoms (BRAS)  |                     |       |       | |
| M ± SD                       | 28.1 ± 21.1         | 39.5 ± 24.5 | 45.8 ± 25.9 | <0.001 |
| Me (Q1; Q3)                  | 22 (11; 44)         | 44 (22; 56) | 50 (22; 67) | |
| Min–Max                      | 0–89                | 0–100 | 0–89 | |
| Concern about hair loss (BRHL) |                     |       |       | |
| M ± SD                       | 51.1 ± 34.5         | 52.7 ± 38.3 | 58.3 ± 33.2 | 0.642 |
| Me (Q1; Q3)                  | 67 (33; 67)         | 67 (33; 100) | 67 (33; 75) | |
| Min–Max                      | 0–100               | 0–100 | 0–100 | |

M—mean; SD—standard deviation; Me—median; Q1—lower quartile; Q3—upper quartile; Min—lowest value; Max—highest value.

### 4. Discussion

Each year, breast cancer contributes to the death of many women. Early diagnosis and advanced diagnostics allow for reducing mortality from breast cancer [8–11]. Modern treatment relies on combination therapy involving surgery, chemotherapy, and radiation therapy. Unfortunately, cancer treatment may produce a number of adverse effects with a patient-specific incidence and severity. Many women perceive the surgical treatment as disfiguring and leading to a loss of femininity [12,13]. The cosmetic effect and intense pain (especially in the arm and breast) contribute to poorer daily functioning and interfere with
professional activity, which is reflected in the patients’ QoL [14]. Research demonstrates the better outcomes of breast reconstruction compared to a mastectomy [15]. The choice of this high safety profile method is strongly associated with an improvement in patient esthetic satisfaction and QoL [16]. Good cosmetic outcome scores have a significant correlation with psychological adjustment [17,18]. In a study by Brunault et al. [19], QoL was dependent on psychological and patient-specific factors (age, depression, coping with stress) more than on biological ones (treatment type, cancer stage).

Carrying the burden of cancer is a major challenge for patients. The strategy that patients use to cope with their breast cancer significantly affects their quality of life. A number of strategies for coping with cancer have been identified, including: fighting spirit, positive redefinition, helplessness/hopelessness, and anxious preoccupation. A patient taking the constructive approach is motivated to treat their illness as a challenge and undertake action to combat it. Positive redefinition allows the patient to find hope and satisfaction in life, while maintaining full awareness of the severity of their illness; meanwhile, destructive strategies manifest in feelings of powerlessness, anxiety, and a tendency to interpret any symptom as a sign of health deterioration. The latter may exacerbate the adverse effects of mastectomy, in particular the arm- and breast-related symptoms, and promote a passive approach to the illness. In published literature, the choice of an active and constructive strategy not only improved QoL but also contributed to longer survival [20–22].

T. Kershaw et al. [23] demonstrated that both constructive and destructive strategies for coping with cancer significantly affected QoL. Their findings suggest a stronger impact of the chosen coping strategy on the psychological QoL aspects than on physical ones. Notably, negative strategies have a strong impact on patients’ lives and impair their daily functioning considerably, while a positive approach to coping with cancer does not improve QoL as strongly. In literature, Chabowski et al. documented the complex relationship between QoL and coping with disease [24]. Moreover, multiple studies show that one’s choice of coping strategy may depend on the stage of treatment and time from diagnosis [25]. The longer the time from diagnosis, the less likely patients are to adopt positive strategies, while no change over time was observed for the “helplessness” and “anxious preoccupation” strategies [26].

Our study corroborates findings from other research papers, showing the patients’ ability to use constructive coping strategies had statistically significant associations with QoL in all functioning domains, as well as with symptom severity and adverse effects of treatment. An important domain affected by an inability to positively cope with the disease, as well as by severe pain, involved sexual functioning and sexual enjoyment. Our study identified a statistically significant link with these domains. This was attributable both to disease symptoms, adverse effects of treatment, or severe stress, and to poorer QoL, e.g., due to depression. Women who had undergone mastectomy did not feel attractive, and their sexuality—an integral, fundamental, natural part of human personality—was affected [27,28]. Sexuality is a crucial factor in QoL, as well as a fundamental bio-socio-psychological contributor to the development of personality, temperament, and enjoyable life experiences; a positive experience of sexuality facilitates coping with cancer, which is why the aspect is relevant to clinicians [29–31].

There is no doubt that severe pain, especially chronic, does reduce QoL. Notably, patients experiencing intense pain rated their QoL much lower in the physical, emotional, social, sexual, and cognitive domains [32]. This also affected their functioning in their social roles. Similar conclusions in this respect come from the present study and from that by Caffo et al. [33]. Notably, patients who experienced mild or no pain obtained much higher QoL scores. Pain after mastectomy can make patients anxious about recurrence, which also affects QoL [33].

An awareness of women’s individual needs, coping strategies, and the impact of pain on their emotional and physical QoL can help make the work of healthcare professionals
more effective and provide women with comprehensive care and support they need in the difficult process of cancer treatment.

5. Conclusions

Patients choosing constructive strategies obtained higher QoL scores, while greater reliance on destructive coping strategies was associated with significantly lower QoL.

In all functioning domains, higher levels of pain were associated with poorer QoL and more severe symptoms associated with the disease and its treatment.

Author Contributions: E.O. conceived the study and drafted and finalized the manuscript. W.M. interpreted the statistical analysis and revised the manuscript. M.C. participated in the data acquisition and reviewed the manuscript. B.J.-P. designed the study and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Medical University Bioethics Committee (approval no. KB-196/2018, approval date 24 April 2018).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All the data analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare that they have no competing interest.

References

1. Burzynska, M.; Maniecka-Bryla, I.; Pikala, M. Trends of mortality due to breast cancer in Poland, 2000–2016. BMC Public Health 2020, 20, 120. [CrossRef]
2. Religioni, U. Cancer incidence and mortality in Poland. Clin. Epidemiol. Glob. Health 2020, 8, 329–334. [CrossRef]
3. Kozierkiewicz, A.; Jassem, J. Current data on the treatment of breast and colorectal cancer in Poland. Nowotw. J. Oncol. 2012, 62, 56–60.
4. Didkowska, J.; Wojciechowska, U. Breast cancer in Poland and Europe—Population and statistics. Nowotw. J. Oncol. 2013, 63, 111–118.
5. Zatorński, W.; Sulkowska, U.; Didkowska, J. Cancer epidemiology in Poland. Nowotw. J. Oncol. 2015, 65, 179–196. [CrossRef]
6. Zawisza, K.; Tobiasz-Adamczyk, B.; Nowak, W.; Kulig, J.; Jedrys, J. Validity and reliability of the quality of life questionnaire (EORTC QLQ C30) and its breast cancer module (EORTC QLQ BR23). Ginekol. Pol. 2010, 81, 262–267. (In Polish) [PubMed]
7. Czerw, A.I.; Marek, E.; Deptała, A. Use of the mini-MAC scale in the evaluation of mental adjustment to cancer. Contemp. Oncol. 2015, 19, 414–419. [CrossRef]
8. Mandelblatt, J.S.; Cronin, K.A.; Bailey, S.; Berry, D.A.; de Koning, H.J.; Draisma, G.; Huang, M.H.; Lee, D.S.J.; Munsell, M.M.; Plevritis, S.K.; et al. Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms. Ann. Intern. Med. 2009, 151, 738–747. [CrossRef] [PubMed]
9. Nyström, L.; Andersson, I.; Bjurstam, N.; Frisell, J.; Nordenskjöld, B.; Rutqvist, L.E. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002, 359, 909–919. [CrossRef]
10. Berry, D.A.; Cronin, K.A.; Plevritis, S.K.; Fryback, D.G.; Clarke, L.; Zelen, M.; Mandelblatt, J.S.; Yakovlev, A.Y.; Habbema, J.D.F.; Feuer, E.J. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 2005, 353, 1784–1792. [CrossRef]
11. Jasiura, A.; Dera, I.; Szlachcic, K.; Gorzel, M.; Zmonarska, J. Breast cancer screening programmes in selected European countries and Poland. J. Educ. Health Sport 2021, 11, 11–21.
12. Koçań, S.; Gürsoy, A. Body image of women with breast cancer after mastectomy: A qualitative research. J. Breast Health 2016, 12, 145–150. [CrossRef] [PubMed]
13. Sukartini, T.; Sari, Y.I.P. Women with breast cancer living with one breast after a mastectomy. Cent. Eur. J. Nurs. Midwifery 2021, 12, 366–375. [CrossRef]
14. D’Egidio, V.; Sestili, C.; Mancino, M.; Sciarrà, I.; Cochiera, R.; Backhaus, I.; Mannucci, A.; de Luca, A.; Frusone, F.; Monti, M.; et al. Counseling interventions delivered in women with breast cancer to improve health-related quality of life: A systematic review. Qual. Life Res. 2017, 26, 2573–2592. [CrossRef] [PubMed]
15. Tarkowska, M.; Głowacka-Mrotek, I.; Nowikiewicz, T.; Goch, A.; Zegarski, W. Quality of Life in Women Subjected to Surgical Treatment of Breast Cancer Depending on the Procedure Performed within the Breast and Axillary Fossa—A Single-Center, One Year Prospective Analysis. J. Clin. Med. 2021, 10, 1339. [CrossRef] [PubMed]
16. Domenici, L.; Caputo, G.G.; Losco, L.; Di Taranto, G.; Lo Torto, F.; Pierazzi, D.M.; Governa, M.; Panici, P.B.; Ribuffo, D.; Cigna, E. Muscle-Sparing Skin-Reducing Breast Reconstruction with Pre-Pectoral Implants in Breast Cancer Patients: Long-Term Assessment of Patients’ Satisfaction and Quality of Life. J. Investig. Surg. 2021, 1–7. [CrossRef] [PubMed]

17. Nicholson, R.M.; Leinster, S.; Sassoon, E.M. A comparison of the cosmetic and psychological outcome of breast reconstruction, breast conserving surgery and mastectomy without reconstruction. Breast 2007, 16, 396–410. [CrossRef]

18. Juhl, A.A.; Christensen, S.; Zachariae, R.; Damsgaard, T.E. Unilateral breast reconstruction after mastectomy–patient satisfaction, aesthetic outcome and quality of life. Acta Oncol. 2017, 56, 225–231. [CrossRef]

19. Brunault, P.; Champagne, A.L.; Huguet, G.; Suzanne, I.; Senon, J.L.; Body, G.; Rusch, E.; Magnin, G.; Voyer, M.; Réveillère, C.; et al. Major depressive disorder, personality disorders, and coping strategies are independent risk factors for lower quality of life in non-metastatic breast cancer patients. Psychooncology 2016, 25, 513–520. [CrossRef]

20. Czerw, A.; Religioni, U.; Deptała, A. Assessment of pain, acceptance of illness, adjustment to life with cancer and coping strategies in breast cancer patients. Breast Cancer 2016, 23, 654–661. [CrossRef]

21. Khalili, N.; Farajzadegan, Z.; Mokarian, F.; Bahrami, F. Coping strategies, quality of life and pain in women with breast cancer. Iran. J. Nurs. Midwifery Res. 2013, 18, 105–111.

22. Bussel, V.A.; Naus, M.J. A longitudinal investigation of coping and posttraumatic growth in breast cancer survivors. J. Psychosoc. Oncol. 2010, 28, 61–78. [CrossRef] [PubMed]

23. Kershaw, T.; Northouse, L.; Kritpracha, C.; Schafenacker, A.; Mood, D. Coping strategies and quality of life in women with advanced breast cancer and their family caregivers. Psychol. Health 2004, 19, 139–155. [CrossRef]

24. Chabowski, M.; Polański, J.; Jankowska-Polańska, B.; Janczak, D.; Rosińczuk, J. Is nutritional status associated with the level of anxiety, depression and pain in patients with lung cancer? J. Thorac. Dis. 2018, 10, 2303–2310. [CrossRef] [PubMed]

25. Sears, S.R.; Stanton, A.L.; Danoff-Burg, S. The yellow brick road and the emerald city: Benefit finding, positive reappraisal coping, and posttraumatic growth in women with early-stage breast cancer. Health Psychol. 2003, 22, 487–497. [CrossRef]

26. Malicka, I.; Szczepańska-Gieracha, J.; Jankowska, E.; Woźnińska, M.; Rymaszewska, J. Physical activity, life satisfaction and adjustment to illness in women after treatment of breast cancer. Contemp. Oncol. 2011, 15, 180–185. [CrossRef]

27. Sheppard, L.A.; Ely, S. Breast cancer and sexuality. Breast J. 2008, 14, 176–181. [CrossRef]

28. Greenberg, J.S.; Bruess, C.E.; Oswalt, S.B. Exploring the Dimensions of Human Sexuality; Jones & Bartlett Publishers: Burlington, MA, USA, 2014.

29. Emilee, G.; Ussher, J.M.; Perz, J. Sexuality after breast cancer: A review. Maturitas 2010, 66, 397–407. [CrossRef] [PubMed]

30. Kedde, H.; Van de Wiel, H.B.M.; Weijmar Schultz, W.C.M.; Wijsen, C. Sexual dysfunction in young women with breast cancer. Supportive Care Cancer 2013, 21, 271–280. [CrossRef]

31. Den Ouden, M.E.M.; Pelgrum-Keurhorst, M.N.; Uitdehaag, M.J.; De Vocht, H.M. Intimacy and sexuality in women with breast cancer: Professional guidance needed. Breast Cancer 2019, 26, 326–332. [CrossRef] [PubMed]

32. Costa, W.A.; Monteiro, M.N.; Queiroz, J.F.; Gonçalves, A.K. Pain and quality of life in breast cancer patients. Clinics 2017, 72, 758–763. [CrossRef]

33. Caffo, O.; Amichetti, M.; Ferro, A.; Lucenti, A.; Valduga, F.; Galligioni, E. Pain and quality of life after surgery for breast cancer. Breast Cancer Res. Treat. 2003, 80, 39–48. [CrossRef] [PubMed]